BioSpace News Archive

Kronos Bio, Inc., a company dedicated to transforming the lives of those affected by cancer, announced that members of the management team will participate in fireside chats at the following investor conferences:

Elicio Therapeutics (Nasdaq: ELTX), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced the closing of its previously announced merger with Angion Biomedica Corp.

Sensei Biotherapeutics, Inc. today announced that the first patient has been dosed in its Phase 1/2 clinical trial evaluating SNS-101 for the treatment of advanced solid tumors.

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) is hosting a Research & Development (R&D) Day today beginning at 9:00 a.m. ET to discuss progress towards the company’s “20 in 25” goal to grow its pipeline of RNAi therapeutics that leverage the proprietary Targeted RNAi Molecule (TRiM™) platform to a total of 20 clinical stage or marketed products in the year 2025.

QurAlis Corporation today announced that Kasper Roet , Ph.D., CEO and co-founder, will participate in the following conferences.

T-knife Therapeutics, Inc. today announced presentation of a poster titled, “MAGE-A1 targeting TK-8001 TCR-T cells currently being investigated in the IMAG1NE Phase 1/2 clinical trial demonstrate broad in vitro and in vivo anti-tumor activity and are superior to human-derived MAGE-A1 TCRs” at the International Society for Cell & Gene Therapy (ISCT) Annual Meeting being held from May 31 – June 3, 2023 in Paris, France.

PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (APT) for the treatment of Autism Spectrum Disorder (ASD), and other serious conditions with intractable neurologic symptoms, today announced that the eligibility review and final enrollment for the company’s Real World Evidence study (HAT-301) has been completed.

Vaccinex, Inc. announced that Maurice Zauderer, Ph.D., President and Chief Executive Officer, will present at the Jefferies Healthcare Conference on Friday, June 9, 2023 at 10:00 to 10:25 am Eastern Time in New York City, NY and invites investors to participate in one-on-one meetings that same day.

Pasithea Therapeutics Corp. announced that pre-clinical results for its lead drug candidate, PAS-004, have been accepted for a poster presentation at the 2023 Neurofibromatosis Conference taking place June 24-27, 2023, in Scottsdale, Arizona.

Lexicon Pharmaceuticals, Inc. announced the pricing of its previously announced underwritten public offering of 23,924,705 shares of its common stock, par value $0.001.